Chemours (CC) reported Q1 EPS of $1.46, $0.56 better than the analyst estimate of $0.90. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.56 billion.
FY 2022 Adjusted EBITDA is now expected to be between $1.475 billion and $1.575 billion vs. prior guidance of between $1.3 billion and $1.425 billion. Free Cash Flow is expected to be greater than $550 million vs. prior guidance of greater than $500 million.